Slate Medicines Secures $130M to Advance Migraine Prevention
February 26, 2026, 9:37 am
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2011
Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headache disorders. It represents a new, clinically validated target. The investment propels SLTE-1009 into Phase 1 trials mid-2026. Subcutaneous dosing is a key design feature, promising patient convenience. RA Capital, Forbion, and Foresite Capital co-led the round. CEO Gregory Oakes leads the experienced team. They aim to serve patients underserved by current options. Slate Medicines seeks to redefine chronic migraine management with its innovative pipeline and strong backing.
Raleigh, NC – Slate Medicines has launched. The biotech company secured $130 million in Series A funding. This significant capital influx positions Slate Medicines to revolutionize migraine prevention. Its focus is next-generation therapeutics. The company aims to address chronic headache disorders with novel treatments.
The substantial Series A round closed on February 24, 2026. It was co-led by prominent healthcare investors. RA Capital Management, Forbion, and Foresite Capital spearheaded the financing. An additional undisclosed biotech investor also participated. These funds will fuel aggressive R&D efforts. They will support expanded operations.
Slate Medicines will advance its lead program, SLTE-1009. This asset is an anti-PACAP monoclonal antibody. DartsBio Pharmaceuticals (Guangdong), Ltd. licensed SLTE-1009 to Slate Medicines. The therapy targets PACAP (pituitary adenylate cyclase-activating polypeptide). PACAP represents a clinically validated target for headache prevention.
Migraine remains a debilitating condition for millions. Many patients find current preventive therapies inadequate. SLTE-1009 offers a distinct approach. It differentiates from CGRP-targeting drugs. This provides a new pathway for relief. It promises hope for those still suffering.
The company has engineered SLTE-1009 for patient convenience. It features half-life extension technology. This allows for subcutaneous dosing. Patients can administer the treatment at home. This capability simplifies therapy. It enhances access to vital medication. Convenience improves adherence, a critical factor in chronic disease management.
Clinical trials are on the horizon. SLTE-1009 is set to initiate Phase 1 trials in mid-2026. This step marks a crucial milestone. It moves the drug closer to patient impact. The company is committed to rigorous testing and development. Safety and efficacy remain paramount.
Slate Medicines boasts a leadership team of seasoned experts. Gregory Oakes serves as CEO and Board Director. He brings over 30 years of biopharma experience. His background includes leadership roles at major clinical-stage and commercial organizations. He previously served as CEO of Landos Biopharma. He also held executive positions at Celgene, Novartis, and Vifor Pharma. Oakes recently acted as a venture partner at Raven, RA Capital’s incubator.
Neil Buckley is the Chief Operating Officer and President. He also co-founded Slate Medicines. He previously served as a venture partner at Raven. Buckley, alongside RA Capital’s Sera Medicines accelerator, established the company. This strategic partnership created a strong foundation.
Dr. Roger Cady is the Chief Medical Officer. He is a renowned headache specialist. Dr. Cady previously held significant neurology leadership roles. These included positions at Alder Biopharmaceuticals and Lundbeck. His expertise strengthens the company’s clinical direction. His insights are invaluable for migraine treatment development.
The financing round also expanded the Board of Directors. Andrew Levin, M.D., Ph.D., Partner at RA Capital, joined the board. Tim Lohoff, Ph.D., Principal at Forbion, also took a seat. Cindy Xiong, Ph.D., Partner at Foresite Capital, completed the new additions. Their collective experience provides robust guidance. They will help navigate complex drug development landscapes.
Slate Medicines’ vision extends beyond SLTE-1009. The company is developing an undisclosed pipeline. These additional programs underscore a commitment to innovation. They aim to address a broader spectrum of headache disorders. The goal is to establish a leading presence in neurology.
The new capital secures the clinical advancement of SLTE-1009. It positions the business strategically. The company plans to redefine migraine prevention. This involves a differentiated product profile. It also centers on convenient at-home dosing. These elements promise improved patient outcomes and quality of life.
This significant investment highlights investor confidence. They see potential in Slate Medicines' approach. The focus on a novel, validated target is key. The experienced leadership team provides stability. The promise of at-home administration excites. Slate Medicines is poised for substantial growth. It prepares to make a lasting impact on chronic migraine treatment. The future of headache care looks brighter.
Biotech Innovator Lands $130 Million for Migraine Breakthrough
Raleigh, NC – Slate Medicines has launched. The biotech company secured $130 million in Series A funding. This significant capital influx positions Slate Medicines to revolutionize migraine prevention. Its focus is next-generation therapeutics. The company aims to address chronic headache disorders with novel treatments.
The substantial Series A round closed on February 24, 2026. It was co-led by prominent healthcare investors. RA Capital Management, Forbion, and Foresite Capital spearheaded the financing. An additional undisclosed biotech investor also participated. These funds will fuel aggressive R&D efforts. They will support expanded operations.
Slate Medicines will advance its lead program, SLTE-1009. This asset is an anti-PACAP monoclonal antibody. DartsBio Pharmaceuticals (Guangdong), Ltd. licensed SLTE-1009 to Slate Medicines. The therapy targets PACAP (pituitary adenylate cyclase-activating polypeptide). PACAP represents a clinically validated target for headache prevention.
Migraine remains a debilitating condition for millions. Many patients find current preventive therapies inadequate. SLTE-1009 offers a distinct approach. It differentiates from CGRP-targeting drugs. This provides a new pathway for relief. It promises hope for those still suffering.
The company has engineered SLTE-1009 for patient convenience. It features half-life extension technology. This allows for subcutaneous dosing. Patients can administer the treatment at home. This capability simplifies therapy. It enhances access to vital medication. Convenience improves adherence, a critical factor in chronic disease management.
Clinical trials are on the horizon. SLTE-1009 is set to initiate Phase 1 trials in mid-2026. This step marks a crucial milestone. It moves the drug closer to patient impact. The company is committed to rigorous testing and development. Safety and efficacy remain paramount.
Slate Medicines boasts a leadership team of seasoned experts. Gregory Oakes serves as CEO and Board Director. He brings over 30 years of biopharma experience. His background includes leadership roles at major clinical-stage and commercial organizations. He previously served as CEO of Landos Biopharma. He also held executive positions at Celgene, Novartis, and Vifor Pharma. Oakes recently acted as a venture partner at Raven, RA Capital’s incubator.
Neil Buckley is the Chief Operating Officer and President. He also co-founded Slate Medicines. He previously served as a venture partner at Raven. Buckley, alongside RA Capital’s Sera Medicines accelerator, established the company. This strategic partnership created a strong foundation.
Dr. Roger Cady is the Chief Medical Officer. He is a renowned headache specialist. Dr. Cady previously held significant neurology leadership roles. These included positions at Alder Biopharmaceuticals and Lundbeck. His expertise strengthens the company’s clinical direction. His insights are invaluable for migraine treatment development.
The financing round also expanded the Board of Directors. Andrew Levin, M.D., Ph.D., Partner at RA Capital, joined the board. Tim Lohoff, Ph.D., Principal at Forbion, also took a seat. Cindy Xiong, Ph.D., Partner at Foresite Capital, completed the new additions. Their collective experience provides robust guidance. They will help navigate complex drug development landscapes.
Slate Medicines’ vision extends beyond SLTE-1009. The company is developing an undisclosed pipeline. These additional programs underscore a commitment to innovation. They aim to address a broader spectrum of headache disorders. The goal is to establish a leading presence in neurology.
The new capital secures the clinical advancement of SLTE-1009. It positions the business strategically. The company plans to redefine migraine prevention. This involves a differentiated product profile. It also centers on convenient at-home dosing. These elements promise improved patient outcomes and quality of life.
This significant investment highlights investor confidence. They see potential in Slate Medicines' approach. The focus on a novel, validated target is key. The experienced leadership team provides stability. The promise of at-home administration excites. Slate Medicines is poised for substantial growth. It prepares to make a lasting impact on chronic migraine treatment. The future of headache care looks brighter.